ArticleNature immunology2024
Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade.
2 registry-linked trialsAbstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 95 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07338981 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation
(CHRONO-RCC) Time-of-day-Dependent Administration of Dual Immune Check Point Inhibitors (ICI) in Advanced Kidney Cancer
NCT07346053 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation
CHRONO-EVP: Time-of-day Dependent Administration of Enfortumab Vedotin and Pembrolizumab (EV/P) in Advanced Bladder Cancer
Who cites it
95 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Circadian Disruption as a Determinant of the Tumor Temporal State in Colorectal Cancer: A PRISMA-Based Systematic Review Integrating Metabolism, Immunity, and Metastasis.International journal of molecular sciences · 2026Pooled it
- Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis.Clinical & experimental metastasis · 2024Pooled it
- Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer.Journal for immunotherapy of cancer · 2026Trial
- Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.Nature medicine · 2026Trial
- Moving for optimal immunity: the effect of acute high-intensity interval training on phenotype, virus specificity and chemokine receptor expression in human CD8+ T cells.Frontiers in immunology · 2025Trial
- Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives.Gut microbes · 2026Review
- Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer.Oncoimmunology · 2026Article
- Role of the circadian rhythm in squamous cell carcinoma: From molecular mechanism to therapy (Review).Molecular medicine reports · 2026Review
- Time matters: circadian genetics and the molecular logic of human health and disease.Nature reviews. Genetics · 2026Review
- Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis.British journal of cancer · 2026Article
- Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression.Oncogene · 2026Article
- SETDB1 cooperates with the CRL4B complex to promote colorectal cancer tumorigenesis by disrupting circadian rhythm.Oncogene · 2026Article
- Unlocking the clock: a systematic review and meta-analysis on optimizing immune checkpoint inhibitor timing for advanced solid tumors.British journal of cancer · 2026Article
- Circadian control of circulating tumour-derived extracellular vesicle secretion affects targeted therapy efficacy.Nature cell biology · 2026Article
- The circadian architecture of tumor immunity: mechanistic insights and treatment strategies.Biomarker research · 2026Review
- Can Disruption of Circadian Rhythms Be Linked to Radiation-Induced Acute Myeloid Leukaemia?Cancers · 2026Review
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Timing matters: how mechanism-guided sequencing shapes the efficacy of radiotherapy-immunotherapy combinations : A systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Bridget M FortinDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0001-9080-6443
Shannon M PfeifferDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0002-4291-9483
Jacob Insua-RodríguezDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.
Hamad AlshetaiwiDepartment of Pathology, University of Hail, Hail, Saudi Arabia.ORCID http://orcid.org/0000-0003-3144-7377
Alexander MoshenskyDepartment of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Wei A SongDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.
Alisa L MahieuDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.
Sung Kook ChunDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0001-8207-0034
Amber N LewisDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.
Alex HsuDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.
Isam AdamDepartment of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Oliver S EngChao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA.
Nicholas R PannunzioDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.
Marcus M SeldinDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0001-8026-4759
Ivan MarazziDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.
Francesco MarangoniDepartment of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Devon A LawsonDepartment of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0003-1692-0517
Kai KessenbrockDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0003-0410-6104
Selma MasriDepartment of Biological Chemistry, University of California Irvine, Irvine, CA, USA. smasri@uci.edu.ORCID http://orcid.org/0000-0002-8619-8331
Funding
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9MCARCINOGENESIST32CA009054 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI EDINGER, AIMEE L, FRUMAN, DAVID ALEXANDER · 1985 to 2025
$8.6MIntegrative approaches to dissection of endocrine communicationDP1DK130640 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI SELDIN, MARCUS MICHAEL · 2021 to 2025
$3.2MCircadian Clock and Myc-dependent Regulation of Cellular TransformationR01CA259370 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Selma Masri · 2022 to 2026
$3.0MCircadian Clock Disruption and Colorectal CancerR01CA244519 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Selma Masri · 2020 to 2026
$3.0MRapid detection of CRLF2 rearrangements in Hispanic Ph-like ALL patients to access diagnosis and relapseR37CA266042 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Nicholas Pannunzio · 2022 to 2026
$2.5MAberrant V(D)J recombination in B cells initiates lymphoid malignancyR01CA276470 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Nicholas Pannunzio · 2024 to 2026
$1.0MDisentangling the Epidermal Immune Crosstalk in Inflammatory Skin DiseaseF31AR083279 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI MOSHENSKY, ALEXANDER · 2023 to 2025
$136kClock Disruption Accelerates Colorectal Cancer and Promotes ImmunosuppressionF31CA287992 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTIN, BRIDGET · 2024 to 2024
$31kNational Science Foundation (NSF) DGE1839285NCI NIH HHS F31 CA287992NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA244519NCI NIH HHS R01 CA259370NCI NIH HHS R01 CA276470NCI NIH HHS R37 CA266042NCI NIH HHS T32 CA009054NIAMS NIH HHS F31 AR083279NIDDK NIH HHS DP1 DK130640U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA244519U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA259370U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA276470U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R37CA266042U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) T32CA009054U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) DP1DK130640
Abstract
The circadian clock is a critical regulator of immunity, and this circadian control of immune modulation has an essential function in host defense and tumor immunosurveillance. Here we use a single-cell RNA sequencing approach and a genetic model of colorectal cancer to identify clock-dependent changes to the immune landscape that control the abundance of immunosuppressive cells and consequent suppression of cytotoxic CD8
Indexed as
B7-H1 AntigenCircadian ClocksImmune Checkpoint InhibitorsMyeloid-Derived Suppressor CellsAnimalsCD8-Positive T-LymphocytesCell Line, TumorCircadian RhythmColorectal NeoplasmsCytokinesFemaleHumansImmune ToleranceImmunosuppression TherapyMaleMiceB7-H1 AntigenCd274 protein, mouseCytokinesImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07338981ClinicalTrials.gov
NCT07346053ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.